Journal
CRITICAL CARE CLINICS
Volume 27, Issue 3, Pages 719-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.ccc.2011.04.004
Keywords
Acute lung injury; ALI; Adult respiratory distress syndrome; ARDS; Mesenchymal stem cells; MSC
Categories
Funding
- NHLBI NIH HHS [R37 HL051856-15, R01 HL051854-16, R37 HL051856, R01 HL051854, U01 HL108713] Funding Source: Medline
Ask authors/readers for more resources
Acute respiratory distress syndrome (ARDS) is a clinical syndrome of acute respiratory failure presenting with hypoxemia and bilateral pulmonary infiltrates, most often in the setting of pneumonia, sepsis, or major trauma. The pathogenesis of ARDS involves lung endothelial injury, alveolar epithelial injury, and the accumulation of protein-rich fluid and cellular debris in the alveolar space. No pharmacologic therapy has so far proved effective. A potential strategy involves cell-based therapies, including mesenchymal stem cells (MSCs). Herein we review basic properties of MSCs, their use in preclinical models of lung injury and ARDS, and potential therapeutic mechanisms.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available